Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Women's Health Rheumatology Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Trial Radar • ClinicalTrials.gov • Registry-linked

Trial Radar

2231 clinical trials with phase, status, specialty and registry links, summarised for rapid clinical review.

2231 recruiting AI clinical summaries
Explore Trial Collections Follow research updates
All Phases Phase I Phase II Phase III Phase IV
Therapeutic Area: All Cardiology / Cardiovascular Dermatology Diabetes / Metabolic Gastroenterology Haematology Infectious Disease Men's Health Mental Health / Psychiatry Nephrology Neurology Oncology Rare Diseases
🔬
Trial Radar

Clinical Trial Intelligence

active not recruiting Phase III
A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis
Trial testing two new drugs alone and combined for generalised myasthenia gravis, measuring safety, effectiveness, and how the body responds.
08 Jul 2026 NCT05070858
active not recruiting Phase III Oncology
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma
Trial testing if adding epcoritamab injections to standard rituximab and lenalidomide improves outcomes in adults with relapsed/refractory follicular lymphoma.
08 Jul 2026 NCT05409066
● Recruiting Phase III Oncology
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
What is being tested: Odronextamab (an experimental bispecific antibody) combined with chemotherapy versus the standard rituximab-chemotherapy regimen in treatment-naïve adult patients with diffuse large…
08 Jul 2026 NCT06091865
● Recruiting Phase III
A Study of Brenipatide in Participants With Alcohol Use Disorder
Brenipatide tested against placebo over 56 weeks to assess whether it safely reduces alcohol use in people with alcohol use disorder.
07 Jul 2026 NCT07219953
active not recruiting Phase III Oncology
Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer
Durvalumab added to standard BCG therapy improved outcomes compared to BCG alone in non-muscle-invasive bladder cancer.
07 Jul 2026 NCT03528694
active not recruiting Phase III
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without Inhibitors
Emicizumab injections prevent bleeding in babies under 12 months with severe haemophilia A, with safety and effectiveness monitored over 8 years.
07 Jul 2026 NCT04431726
● Recruiting Phase III Diabetes / Metabolic
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
A trial testing whether eloralintide injection reduces knee osteoarthritis pain in overweight or obese adults over 75 weeks.
07 Jul 2026 NCT07353931
● Recruiting Phase III Gastroenterology
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn’s Disease
This trial tests a new drug called Afimkibart to treat moderate-to-severe Crohn's disease, comparing it against placebo.
06 Jul 2026 NCT06819891
● Recruiting Phase II / Phase III
A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)
A trial testing whether a new drug (atumelnant) safely and effectively treats congenital adrenal hyperplasia in children.
06 Jul 2026 NCT07159841
● Recruiting Phase III
A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism
Baxdrostat reduced blood pressure and normalised hormone levels better than placebo in primary aldosteronism patients.
06 Jul 2026 NCT07007793
active not recruiting Phase III Oncology
An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS
Apalutamide combined with hormone therapy improved metastasis-free survival in high-risk prostate cancer patients receiving radiotherapy.
06 Jul 2026 NCT02531516
● Recruiting Phase III Rheumatology
A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)
Trial testing whether baricitinib is safe and effective for treating systemic juvenile idiopathic arthritis in children aged 1-18 years.
06 Jul 2026 NCT04088396
● Recruiting Phase III Cardiology / Cardiovascular
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
What is being tested: JNJ-79635322 is being directly compared with a BCMA×CD3 bispecific antibody—both novel immunotherapies designed to engage T cells against BCMA-expressing myeloma…
06 Jul 2026 NCT07258511
active not recruiting Phase III
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
Trial comparing iberdomide versus lenalidomide as maintenance therapy after stem cell transplant in newly diagnosed myeloma patients.
02 Jul 2026 NCT05827016
active not recruiting Phase III Infectious Disease
A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy
Two-drug HIV treatment works as well as three-drug treatment, with simpler dosing and fewer side effects in treatment-naive adults.
02 Jul 2026 NCT05979311
● Recruiting Phase III Oncology
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
Treatment being tested: Trastuzumab deruxtecan (T-DXd) combined with pembrolizumab compared to platinum-based chemotherapy with pembrolizumab as first-line therapy for HER2-overexpressing advanced non-squamous non-small cell…
02 Jul 2026 NCT06899126
● Recruiting Phase III Cardiology / Cardiovascular
Thromboprophylaxis in Lower Limb Immobilisation
What is being tested: The clinical and cost effectiveness of thromboprophylaxis (blood clot prevention) in patients immobilised with plaster casts or splints following injury,…
02 Jul 2026 NCT06370273
● Recruiting Phase III
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
Trial testing whether atogepant tablets safely reduce migraine frequency in children and teenagers aged 6-17 years over 12 weeks.
01 Jul 2026 NCT05711394
active not recruiting Phase III
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)
Gene-edited stem cell therapy significantly improves severe sickle cell disease in children who cannot tolerate standard treatment.
01 Jul 2026 NCT05329649
active not recruiting Phase III
Open-Label Extension Study of BBP-418 (Ribitol) for LGMD2I/R9
Long-term safety and effectiveness study of oral ribitol for a rare inherited muscle weakness condition in previous trial participants.
01 Jul 2026 NCT07678775
active not recruiting Phase III Oncology
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
Adding abemaciclib to standard hormone therapy may delay cancer progression in men with advanced prostate cancer.
01 Jul 2026 NCT05288166
● Recruiting Phase III Rheumatology
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn’s Disease
What is being tested: Duvakitug, a novel therapeutic agent, is undergoing Phase 3 evaluation for induction of remission in moderately to severely active Crohn's…
01 Jul 2026 NCT07184931
● Recruiting Phase III Oncology
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
Treatment being tested: TDXd (trastuzumab deruxtecan) combined with chemotherapy and pembrolizumab versus standard chemotherapy plus trastuzumab and pembrolizumab as first-line therapy for metastatic HER2-positive…
01 Jul 2026 NCT06731478
● Recruiting Phase III
A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome
Clemizole added to standard treatment reduced seizures more than placebo in Dravet syndrome patients.
30 Jun 2026 NCT04462770
● Recruiting Phase III Women's Health
A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A
Long-term study evaluating Mim8, a new factor VIII replacement therapy, for preventing bleeds in haemophilia A patients with or without inhibitors.
30 Jun 2026 NCT05685238
● Recruiting Phase II / Phase III
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
Trial comparing new eye injection tiespectus against standard aflibercept treatment for wet age-related macular degeneration.
30 Jun 2026 NCT07440225
● Recruiting Phase III Diabetes / Metabolic
A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes
What is being tested: VX-880 is an investigational infusion therapy being evaluated for safety, tolerability, and efficacy in treating Type 1 diabetes, specifically targeting…
30 Jun 2026 NCT04786262
● Recruiting Phase III Cardiology / Cardiovascular
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
What is being tested: NNC0487-0111, a novel investigational therapy, is being evaluated against placebo for safety and efficacy in patients with HFpEF or HFmrEF…
30 Jun 2026 NCT07567001
● Recruiting Phase III Oncology
Adjuvant Tebentafusp in High Risk Ocular Melanoma
Treatment being tested: Tebentafusp (a TCR-engineered T-cell therapy) as adjuvant therapy following primary treatment in patients with high-risk uveal melanoma, aiming to prevent recurrence…
30 Jun 2026 NCT06246149
active not recruiting Phase III Oncology
A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer
Adding lurbinectedin to atezolizumab maintenance therapy versus atezolizumab alone for extensive-stage small-cell lung cancer after initial chemotherapy.
29 Jun 2026 NCT05091567
● Recruiting Phase III Cardiology / Cardiovascular
KHENERFIN Study: A Trial to Evaluate the Efficacy and Safety of Sonlicromanol in Primary Mitochondrial Diseases
Treatment being tested: Sonlicromanol, a novel investigational medicine designed to reduce fatigue symptoms and improve physical function (including balance control) in patients with primary…
29 Jun 2026 NCT06451757
● Recruiting Phase III Cardiology / Cardiovascular
Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant IR Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency
What is being tested: Deucrictibant XR (extended-release) tablet for preventative treatment and deucrictibant IR (immediate-release) capsule for acute attack management in acquired angioedema due…
26 Jun 2026 NCT07266805
active not recruiting Phase III Rheumatology
A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)
New drug JNJ-77242113 tested for treating psoriasis in difficult-to-treat areas like scalp, genitals, palms and soles.
25 Jun 2026 NCT06095102
● Recruiting Phase III Dermatology
A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
Tralokinumab injections plus steroid cream safely and effectively treat moderate-to-severe eczema in young children and infants.
25 Jun 2026 NCT06311682
● Recruiting Phase III Diabetes / Metabolic
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Efruxifermin tested against placebo in 1,650 patients with liver scarring from fatty liver disease (stages 2-3, non-cirrhotic).
25 Jun 2026 NCT06215716
● Recruiting Phase III Oncology
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
What is being tested: The combination of TTFields (tumour-treating fields) delivered via NovoTTF-200T device alongside pembrolizumab immunotherapy and platinum-based chemotherapy in patients with metastatic…
25 Jun 2026 NCT06216301
● Recruiting Phase III
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
Trial testing a new drug (volrustomig) versus monitoring in head and neck cancer patients after chemoradiotherapy.
24 Jun 2026 NCT06129864
● Recruiting Phase III
Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS
This trial tests whether pridopidine slows ALS progression compared to placebo in adults over 96 weeks.
24 Jun 2026 NCT07322003
active not recruiting Phase III
A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease
Venglustat compared to standard treatment for reducing heart thickening in adults with Fabry disease over 18 months.
24 Jun 2026 NCT05280548
● Recruiting Phase III Cardiology / Cardiovascular
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
What is being tested: A novel combination therapy pairing elranatamab (a bispecific antibody engaging T-cells and myeloma cells) with daratumumab and lenalidomide, compared against…
24 Jun 2026 NCT05623020
active not recruiting Phase III
A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT)
Mitapivat reduced anaemia in patients with non-transfusion-dependent thalassemia compared to placebo.
23 Jun 2026 NCT04770753
● Recruiting Phase III Mental Health / Psychiatry
NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Trial testing whether adding NBI-1065845 to existing depression treatment works better than placebo for improving symptoms.
23 Jun 2026 NCT06963021
● Recruiting Phase III Oncology
A Study of ZL-1310 Versus Investigator’s Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
What is being tested: ZL-1310, a novel therapeutic agent, is being compared against standard investigator-selected treatments in patients with relapsed small cell lung cancer…
23 Jun 2026 NCT07218146
● Recruiting Phase III Diabetes / Metabolic
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
Intervention being tested: Enicepatide (RO7795068), a dual GLP-1/GIP receptor agonist at multiple doses, compared with placebo for weight management and glycaemic control in patients…
23 Jun 2026 NCT07351058
● Recruiting Phase III Diabetes / Metabolic
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
Treatment being tested: Enicepatide (RO7795068), a dual GLP-1/GIP receptor agonist, is being evaluated at multiple doses versus placebo for weight management efficacy and safety…
23 Jun 2026 NCT07351045
active not recruiting Phase III Oncology
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
Ongoing access to avelumab treatment for patients benefiting from it in completed Pfizer trials, with safety monitoring.
22 Jun 2026 NCT05059522
active not recruiting Phase II / Phase III Rheumatology
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
Litifilimab injections tested for efficacy and safety in adults with active cutaneous lupus unresponsive to antimalarial therapy.
22 Jun 2026 NCT05531565
● Recruiting Phase III Neurology
A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
This trial tests whether inhaled alprazolam stops prolonged seizures faster than placebo in people aged 12+.
22 Jun 2026 NCT05077904
● Recruiting Phase III Oncology
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
What is being tested: Sacituzumab govitecan-hziyah (Sac-TMT), an antibody-drug conjugate targeting TROP-2, is being evaluated as a treatment option for advanced ovarian cancer patients…
22 Jun 2026 NCT07318558
active not recruiting Phase III Oncology
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
New cancer drug inavolisib plus fulvestrant compared with alpelisib plus fulvestrant for advanced breast cancer resistant to previous treatments.
18 Jun 2026 NCT05646862